$ESMC
ESCALON MEDICAL CORP

2020 Q2 Form 10-K Financial Statement

#000086266820000008 Filed on September 28, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 2019 Q3
Revenue $2.015M $9.400M $2.288M
YoY Change -11.66% -2.35% 1.31%
Cost Of Revenue $1.288M $5.198M $1.177M
YoY Change 15.37% 4.01% -2.2%
Gross Profit $726.8K $4.202M $1.111M
YoY Change -37.58% -9.22% 5.31%
Gross Profit Margin 36.07% 44.7% 48.57%
Selling, General & Admin $877.5K $3.874M $999.4K
YoY Change -9.58% -6.47% -0.28%
% of Gross Profit 120.74% 92.2% 89.93%
Research & Development $313.9K $1.122M $245.6K
YoY Change 57.73% 51.71% 154.79%
% of Gross Profit 43.19% 26.71% 22.1%
Depreciation & Amortization $12.87K $50.08K $11.91K
YoY Change -56.75% -0.11% -9.71%
% of Gross Profit 1.77% 1.19% 1.07%
Operating Expenses $1.191M $4.997M $1.245M
YoY Change 1.87% 2.35% 13.33%
Operating Profit -$464.6K -$1.400M -$133.7K
YoY Change 8835.19% 453.32% 208.21%
Interest Expense -$3.800K $13.58K $3.984K
YoY Change 190.08% -21.74% -41.85%
% of Operating Profit
Other Income/Expense, Net $0.00 $749.4K $755.1K
YoY Change 25397.89% -17495.07%
Pretax Income -$468.4K -$650.3K $621.4K
YoY Change 7106.62% 160.09% -1342.74%
Income Tax
% Of Pretax Income
Net Earnings -$468.4K -$650.3K $621.4K
YoY Change 87.36% 160.1% -1401.69%
Net Earnings / Revenue -23.25% -6.92% 27.16%
Basic Earnings Per Share -$0.09 $0.08
Diluted Earnings Per Share -$63.17K -$0.09 $0.05
COMMON SHARES
Basic Shares Outstanding 7.415M shares 7.415M shares 7.415M shares
Diluted Shares Outstanding 7.415M shares 12.19M shares

Balance Sheet

Concept 2020 Q2 2020 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $826.0K $826.0K $415.8K
YoY Change 101.58% 101.58% -54.31%
Cash & Equivalents $826.0K $826.0K $415.8K
Short-Term Investments
Other Short-Term Assets $154.2K $409.5K $227.7K
YoY Change -30.88% -22.47% -11.43%
Inventory $1.785M $1.785M $1.785M
Prepaid Expenses
Receivables $1.313M $1.313M $1.355M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $4.333M $4.333M $4.153M
YoY Change 1.7% 0.48% -9.92%
LONG-TERM ASSETS
Property, Plant & Equipment $97.21K $1.204M $60.90K
YoY Change 43.18% 1673.7% -18.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $62.79K $62.79K $62.79K
YoY Change
Total Long-Term Assets $1.389M $1.389M $1.921M
YoY Change 60.32% 70.54% 129.82%
TOTAL ASSETS
Total Short-Term Assets $4.333M $4.333M $4.153M
Total Long-Term Assets $1.389M $1.389M $1.921M
Total Assets $5.723M $5.723M $6.074M
YoY Change 11.61% 11.61% 11.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $760.6K $760.6K $691.4K
YoY Change 14.12% 14.12% 1.82%
Accrued Expenses $681.0K $1.072M $619.4K
YoY Change 3.71% 39.39% -16.76%
Deferred Revenue $14.32K
YoY Change -10.53%
Short-Term Debt $201.6K $422.9K $201.6K
YoY Change 0.0% 109.78% 0.0%
Long-Term Debt Due $3.400K $3.400K $3.490K
YoY Change 0.0% 0.0%
Total Short-Term Liabilities $2.865M $2.865M $2.432M
YoY Change 26.76% 26.76% 4.76%
LONG-TERM LIABILITIES
Long-Term Debt $440.2K $440.2K $13.98K
YoY Change 2854.43% 2854.43% -30.1%
Other Long-Term Liabilities $8.872K $905.4K $844.5K
YoY Change -98.71% 31.2% 14.12%
Total Long-Term Liabilities $1.346M $1.346M $858.5K
YoY Change 90.87% 90.87% 12.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.865M $2.865M $2.432M
Total Long-Term Liabilities $1.346M $1.346M $858.5K
Total Liabilities $4.211M $4.211M $3.290M
YoY Change 42.0% 42.0% 6.77%
SHAREHOLDERS EQUITY
Retained Earnings -$68.84M -$67.57M
YoY Change 0.95% -0.62%
Common Stock $7.415K $7.415K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.512M $1.512M $2.784M
YoY Change
Total Liabilities & Shareholders Equity $5.723M $5.723M $6.074M
YoY Change 11.61% 11.61% 11.53%

Cashflow Statement

Concept 2020 Q2 2020 2019 Q3
OPERATING ACTIVITIES
Net Income -$468.4K -$650.3K $621.4K
YoY Change 87.36% 160.1% -1401.69%
Depreciation, Depletion And Amortization $12.87K $50.08K $11.91K
YoY Change -56.75% -0.11% -9.71%
Cash From Operating Activities -$497.9K -$168.5K $7.166K
YoY Change 391.33% -64.35% -39.44%
INVESTING ACTIVITIES
Capital Expenditures -$20.78K -$59.75K $0.00
YoY Change 33.12% 170.12% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$20.78K -$59.75K -$9.390K
YoY Change 33.12% 170.16% 44.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 649.1K $646.6K -$822.00
YoY Change -80239.51% 1819.74% -102.28%
NET CHANGE
Cash From Operating Activities -497.9K -$168.5K $7.166K
Cash From Investing Activities -20.78K -$59.75K -$9.390K
Cash From Financing Activities 649.1K $646.6K -$822.00
Net Change In Cash 130.5K $418.4K $6.344K
YoY Change -210.82% -190.73% -84.67%
FREE CASH FLOW
Cash From Operating Activities -$497.9K -$168.5K $7.166K
Capital Expenditures -$20.78K -$59.75K $0.00
Free Cash Flow -$477.1K -$108.7K $7.166K
YoY Change 456.56% -75.86% -67.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0000862668
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7415329 shares
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2019Q4 dei Entity Public Float
EntityPublicFloat
446137 USD
CY2020 dei Entity Registrant Name
EntityRegistrantName
ESCALON MEDICAL CORP.
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020Q2 esmc Accruedinterestrelatedparty
Accruedinterestrelatedparty
112389 USD
CY2019 esmc Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0 USD
CY2020 esmc Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-344608 USD
CY2019 esmc Increasedecreaseinliabilitiesofdiscontinuedoperations
Increasedecreaseinliabilitiesofdiscontinuedoperations
-1599 USD
CY2020 esmc Increasedecreaseinliabilitiesofdiscontinuedoperations
Increasedecreaseinliabilitiesofdiscontinuedoperations
-943 USD
CY2020Q2 esmc Interestportioninthefutureleasepayments
Interestportioninthefutureleasepayments
144120 USD
CY2020 esmc Maximum Maturity Of Highly Liquid Investments Period
MaximumMaturityOfHighlyLiquidInvestmentsPeriod
P90D
CY2020Q2 esmc Netpresentvalueofnewleasefuturepayments
Netpresentvalueofnewleasefuturepayments
1175167 USD
CY2019Q4 esmc Newleaseliabilities
Newleaseliabilities
285000 USD
CY2020 esmc Pp Ploanamount
PPPloanamount
500000 USD
CY2020Q2 esmc Share Based Compensation Arrangementby Share Based Payment Award Unvested
ShareBasedCompensationArrangementbyShareBasedPaymentAwardUnvested
0 shares
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
666510 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
760621 USD
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1496105 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1312935 USD
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
656707 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
681047 USD
CY2019Q2 us-gaap Accrued Rent Current And Noncurrent
AccruedRentCurrentAndNoncurrent
70587 USD
CY2020Q2 us-gaap Accrued Rent Current And Noncurrent
AccruedRentCurrentAndNoncurrent
0 USD
CY2019Q2 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
0.04
CY2020 us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
0 USD
CY2020Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
2.15 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000 shares
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
827948 USD
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
832040 USD
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69702043 USD
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69702043 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
0 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
0 USD
CY2019 us-gaap Advertising Expense
AdvertisingExpense
33000 USD
CY2020 us-gaap Advertising Expense
AdvertisingExpense
17000 USD
CY2019Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
111000 USD
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
123000 USD
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4986120 shares
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5275060 shares
CY2019Q2 us-gaap Assets
Assets
5127438 USD
CY2020Q2 us-gaap Assets
Assets
5722577 USD
CY2019Q2 us-gaap Assets Current
AssetsCurrent
4260921 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
4333397 USD
CY2018Q2 us-gaap Cash
Cash
1124002 USD
CY2019Q2 us-gaap Cash
Cash
662878 USD
CY2020Q2 us-gaap Cash
Cash
1081239 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
874002 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
409743 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
825958 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1124002 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
662878 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
662878 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1081239 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-461124 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
418361 USD
CY2020 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
4300000
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000 shares
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7415329 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7415329 shares
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7415329 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7415329 shares
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
7415 USD
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
7415 USD
CY2020 us-gaap Common Stock Voting Rights
CommonStockVotingRights
0.7781
CY2020 us-gaap Concentration Risk Benchmark Description
ConcentrationRiskBenchmarkDescription
0.1
CY2019 us-gaap Concentration Risk Supplier
ConcentrationRiskSupplier
two
CY2020 us-gaap Concentration Risk Supplier
ConcentrationRiskSupplier
two
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16006 USD
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
14320 USD
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4997461 USD
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5197866 USD
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2020Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.01
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
44287 USD
CY2020Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
25728 USD
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
102002 USD
CY2020Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
69432 USD
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Warranty Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves
6736 USD
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-8061 USD
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2019Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
156808 USD
CY2020Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
25631 USD
CY2018Q2 us-gaap Deferred Revenue
DeferredRevenue
481000 USD
CY2019Q2 us-gaap Deferred Revenue
DeferredRevenue
427000 USD
CY2020Q2 us-gaap Deferred Revenue
DeferredRevenue
516000 USD
CY2019 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
888000 USD
CY2020 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
1052000 USD
CY2019Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
426803 USD
CY2020Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
516053 USD
CY2019 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
942000 USD
CY2020 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
963000 USD
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
12653 USD
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-2303 USD
CY2019Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7776465 USD
CY2020Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7634924 USD
CY2019Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2020Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2019Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
156808 USD
CY2020Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
25631 USD
CY2019Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7102298 USD
CY2020Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7212393 USD
CY2019Q2 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
127642 USD
CY2020Q2 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
69196 USD
CY2019Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards General Business
DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
207698 USD
CY2020Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards General Business
DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
207698 USD
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
40565 USD
CY2020Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
43741 USD
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits
166317 USD
CY2020Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits
0 USD
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
23207 USD
CY2020Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Warranty Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves
6736 USD
CY2019Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7619657 USD
CY2020Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7609293 USD
CY2019Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
156808 USD
CY2020Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
25631 USD
CY2019Q2 us-gaap Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate
DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
0.045
CY2019Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
51915 USD
CY2020Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
62789 USD
CY2019 us-gaap Dilutive Securities Effect On Basic Earnings Per Share Other
DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
0 USD
CY2018Q2 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
0.03
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
50139 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
50084 USD
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.05
CY2020 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
605006 USD
CY2019 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
-0.16
CY2019 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
0 USD
CY2020 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
-758021 USD
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
396609 USD
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
417829 USD
CY2020Q2 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.3670
CY2019Q2 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
189790 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
137082 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
188755 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
263588 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
256311 USD
CY2019 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2020 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
605005 USD
CY2019 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
259546 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
272881 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
321497 USD
CY2019 us-gaap Financing Receivable Allowance For Credit Losses Recovery
FinancingReceivableAllowanceForCreditLossesRecovery
5450 USD
CY2020 us-gaap Financing Receivable Allowance For Credit Losses Recovery
FinancingReceivableAllowanceForCreditLossesRecovery
0 USD
CY2019Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
141700 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
122050 USD
CY2020Q2 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
0.0614
CY2019Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
112389 USD
CY2020Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
112389 USD
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.21
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0 USD
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
137666 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
94111 USD
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
103522 USD
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-171162 USD
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-105325 USD
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
94929 USD
CY2019 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-54377 USD
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
89250 USD
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
55446 USD
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-93830 USD
us-gaap Lessee Operating Lease Lease Not Yet Commenced Residual Value Guarantee Description
LesseeOperatingLeaseLeaseNotYetCommencedResidualValueGuaranteeDescription
495000
CY2019 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
25373 USD
CY2020 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-68885 USD
CY2019 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
0 USD
CY2020 us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
8872 USD
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 USD
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
10874 USD
CY2019 us-gaap Increase Decrease In Pension And Postretirement Obligations
IncreaseDecreaseInPensionAndPostretirementObligations
-59386 USD
CY2020 us-gaap Increase Decrease In Pension And Postretirement Obligations
IncreaseDecreaseInPensionAndPostretirementObligations
-33964 USD
CY2019 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
CY2020 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
CY2019Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
605006 USD
CY2020Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
0 USD
CY2019 us-gaap Interest Expense
InterestExpense
17353 USD
CY2020 us-gaap Interest Expense
InterestExpense
13580 USD
CY2019 us-gaap Interest Paid Net
InterestPaidNet
44315 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
15387 USD
CY2019Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
1013 USD
CY2020Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
1224 USD
CY2019Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
778621 USD
CY2019Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
779000 USD
CY2019Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
849453 USD
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
849000 USD
CY2019Q2 us-gaap Inventory Net
InventoryNet
1879000 USD
CY2019Q2 us-gaap Inventory Net
InventoryNet
1878860 USD
CY2019Q3 us-gaap Inventory Net
InventoryNet
1785030 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
1785030 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
1785000 USD
CY2019Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
875000 USD
CY2019Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
874985 USD
CY2019Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
612721 USD
CY2020Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
613000 USD
CY2019Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
225254 USD
CY2019Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
225000 USD
CY2019Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
322856 USD
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
323000 USD
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
9170 USD
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
3592 USD
CY2019 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
455000 USD
CY2020 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
407757 USD
CY2019Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2019Q3 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P12M
CY2019Q2 us-gaap Liabilities
Liabilities
2965199 USD
CY2020Q2 us-gaap Liabilities
Liabilities
4210618 USD
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5127438 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5722577 USD
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2260209 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2865007 USD
CY2019Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
704990 USD
CY2020Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1345611 USD
CY2019Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
90933 USD
CY2020Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
89990 USD
CY2019Q2 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
0 USD
CY2020Q2 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
8872 USD
CY2020Q2 us-gaap Line Of Credit Facility Fair Value Of Amount Outstanding
LineOfCreditFacilityFairValueOfAmountOutstanding
201575 USD
CY2020Q2 us-gaap Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
0.05
CY2019 us-gaap Line Of Credit Facility Periodic Payment Interest
LineOfCreditFacilityPeriodicPaymentInterest
17353 USD
CY2020 us-gaap Line Of Credit Facility Periodic Payment Interest
LineOfCreditFacilityPeriodicPaymentInterest
11418 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33682 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
646607 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22117 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59751 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-472689 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-168495 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-250016 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-650280 USD
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-301616 USD
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-702021 USD
CY2019 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-301616 USD
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-650280 USD
CY2019 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-301616 USD
CY2020 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-702021 USD
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2939 USD
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
749383 USD
CY2019Q2 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
3401 USD
CY2020Q2 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
3401 USD
CY2019 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
9879618 USD
CY2020 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
10799694 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-252955 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-1399663 USD
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1208000 USD
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
278634 USD
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
896533 USD
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1107127 USD
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1137878 USD
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1138000 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M1D
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1360981 USD
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1319287 USD
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
96830 USD
CY2019Q2 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
101891 USD
CY2020Q2 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
0 USD
CY2019Q2 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
690094 USD
CY2020Q2 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
0 USD
CY2019 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
70968 USD
CY2020 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
122709 USD
CY2019 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
51600 USD
CY2020 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
51741 USD
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2000000 shares
CY2019 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
22117 USD
CY2020 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
59751 USD
CY2019Q2 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current And Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent
791985 USD
CY2019 us-gaap Pension And Other Postretirement Benefit Contributions
PensionAndOtherPostretirementBenefitContributions
8491 USD
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
978 USD
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Receivable Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsReceivableRemainderOfFiscalYear
356414 USD
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Receivable Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsReceivableRemainderOfFiscalYear
336596 USD
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
39832 USD
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
115420 USD
CY2019Q2 us-gaap Other Assets Current
OtherAssetsCurrent
223078 USD
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
154193 USD
CY2020 us-gaap Other Income
OtherIncome
758000 USD
CY2020Q2 us-gaap Other Long Term Debt
OtherLongTermDebt
9000 USD
CY2019Q2 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
14896 USD
CY2020Q2 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
11503 USD
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11122 USD
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
759371 USD
CY2019Q2 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
0 USD
CY2020Q2 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
221297 USD
CY2019 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
0 USD
CY2020 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
342058 USD
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2000000 shares
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
645000 USD
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
645000 USD
CY2019 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
36575 USD
CY2020 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
0 USD
CY2019Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
32078 USD
CY2020Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
32078 USD
CY2019Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
895844 USD
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
929254 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
67896 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
97214 USD
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.21
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
213000 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
157000 shares
CY2019 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
0 USD
CY2020 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
12008 USD
CY2020 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
645000 USD
CY2020Q2 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
645000 USD
CY2020 us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.0125
CY2019 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2893 USD
CY2020 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3393 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
739765 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1122324 USD
CY2018Q2 us-gaap Restricted Cash
RestrictedCash
250000 USD
CY2019Q2 us-gaap Restricted Cash
RestrictedCash
253135 USD
CY2020Q2 us-gaap Restricted Cash
RestrictedCash
255281 USD
CY2019Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
253135 USD
CY2020Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
255281 USD
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68192219 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68842499 USD
CY2019 us-gaap Revenues
Revenues
9626663 USD
CY2020 us-gaap Revenues
Revenues
9400031 USD
CY2019Q2 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
100582 USD
CY2020Q2 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
100176 USD
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4142392 USD
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3874498 USD
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
213000 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
157000 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.48
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.47
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
154500 shares
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
56000 shares
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
367500 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
157000 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.78
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.48
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.47
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.51
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.00
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.00
CY2019Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
201575 USD
CY2020Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
201575 USD
CY2020 us-gaap Short Term Lease Payments
ShortTermLeasePayments
391384 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
2412255 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
2162239 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
1511959 USD
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
56940 USD
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10364 USD
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7415329 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7415329 shares
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7415329 shares
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7415329 shares
CY2020 us-gaap Advertising Costs Policy Capitalized Direct Response Advertising
AdvertisingCostsPolicyCapitalizedDirectResponseAdvertising
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Advertising costs are charged to operations as incurred. Advertising expense for the years ended June&#160;30, 2020 and 2019 was </font><font style="font-family:inherit;font-size:10pt;">$17,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$33,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div>
CY2020 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the &#8220;Company&#8221; collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (&#8220;Sonomed&#8221;), Escalon Digital Solutions, Inc. (&#8220;EMI&#8221;), Escalon Holdings, Inc. (&#8220;EHI&#8221;), Escalon IP Holdings, Inc., and Sonomed IP Holdings, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the &#8220;FDA&#8221;). The FDA and other government authorities require extensive testing of new products prior to sale and have jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) a pandemic. This pandemic has had a significant impact on the global and domestic economy, and has and is likely to continue to impact the operations of the Company. The Company has been assessing the impact of the COVID-19 pandemic on the business, including the impact on the financial condition and results of operations,&#160;financial resources, changes in accounting judgment as well as the impact on the supply and demand, etc. The Company is considered an essential business and has been able to maintain operations during the lockdown. The Company applied for and received </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;"> in April 2020 under the Payroll Protection Program ("PPP loan") which will help reverse the negative impact in terms of the liquidity. The maturity date is two years from the date of the note. The interest rate is </font><font style="font-family:inherit;font-size:10pt;">1.00%</font><font style="font-family:inherit;font-size:10pt;"> per year. The Company remains in strong communications with the customers and there is no evidence showing that COVID-19 will greatly effect collection of accounts receivable as of date of this filing. However, the Company does not know the extent and duration of the impact of COVID-19 on its business due to the uncertainty about the spread of the virus. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company&#8217;s common stock trades on the OTCQB Market under the symbol &#8220;ESMC.&#8221;</font></div></div>
CY2020 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease deposits of </font><font style="font-family:inherit;font-size:10pt;">$51,915</font><font style="font-family:inherit;font-size:10pt;"> in the June&#160;30, 2019 consolidated balance sheet has been reclassed from other current assets to other assets to be in conformity with the current period presentation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally affected in the US Generally Accepted Accounting Principles ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0000862668-20-000008-index-headers.html Edgar Link pending
0000862668-20-000008-index.html Edgar Link pending
0000862668-20-000008.txt Edgar Link pending
0000862668-20-000008-xbrl.zip Edgar Link pending
esmc-20200630.xml Edgar Link completed
esmc-20200630.xsd Edgar Link pending
esmc-20200630_cal.xml Edgar Link unprocessable
esmc-20200630_def.xml Edgar Link unprocessable
esmc-20200630_lab.xml Edgar Link unprocessable
esmc-20200630_pre.xml Edgar Link unprocessable
esmc_20200630-10k.htm Edgar Link pending
esmc_20200630-10kex231.htm Edgar Link pending
esmc_20200630-10kex311.htm Edgar Link pending
esmc_20200630-10kex312.htm Edgar Link pending
esmc_20200630-10kex321.htm Edgar Link pending
esmc_20200630-10kex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending